CHADS2 score, statin therapy, and risks of atrial fibrillation

Chen Ying Hung, Ching Heng Lin, El Wui Loh, Chih Tai Ting, Tsu Juey Wu

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Objective: Little is known about the effectiveness of statins on primary prevention of atrial fibrillation in elderly patients. This study aimed to evaluate the efficacy of statin treatment for atrial fibrillation prevention in elderly patients with hypertension, and to determine if comorbidity or CHADS2 (Congestive heart failure, Hypertension, Age ≥75 years, Diabetes mellitus, prior Stroke or transient ischemic attack) score can predict the effectiveness of statin treatment. Methods: Patients aged ≥65 years with hypertension were identified from a National Health Insurance research database (a systemic sampling from 2000 to 2009 with a total of 1,000,000 subjects). Medical records of 27,002 patients were used in this study, in which 2400 (8.9%) were receiving statin therapy. Risk of new-onset atrial fibrillation in statin users and nonusers was analyzed. Results: During the 9-year follow-up period, 2241 patients experienced new-onset atrial fibrillation. Statin users were younger than nonusers (72.4 vs 73.4 years) but had a higher prevalence of ischemic heart disease, diabetes mellitus, stroke, and chronic renal disease. Overall, statin therapy reduced the risk of atrial fibrillation by 19% (adjusted hazard ratio 0.81; 95% confidence interval, 0.69-0.95; P =.009). Subgroup analysis showed that statin use was beneficial in patients with or without a particular comorbidity. The effectiveness of statins was significant in patients with CHADS2 score ≥2 (adjusted hazard ratio 0.69; 95% confidence interval, 0.57-0.85; P <.001). However, statin therapy was not as beneficial in hypertensive patients without other cardiovascular comorbidities (CHADS 2 score =1). Conclusion: Statin therapy in elderly patients with hypertension reduces the risk of new-onset atrial fibrillation. Statins are more beneficial in patients with CHADS2 score ≥2 than in those with score of 1.

Original languageEnglish
JournalAmerican Journal of Medicine
Volume126
Issue number2
DOIs
Publication statusPublished - Feb 1 2013
Externally publishedYes

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Atrial Fibrillation
Therapeutics
Hypertension
Comorbidity
Diabetes Mellitus
Stroke
Confidence Intervals
Transient Ischemic Attack
National Health Programs
Primary Prevention
Chronic Renal Insufficiency
Medical Records
Myocardial Ischemia

Keywords

  • Atrial fibrillation
  • CHADS score
  • Hypertension
  • Statins

ASJC Scopus subject areas

  • Medicine(all)

Cite this

CHADS2 score, statin therapy, and risks of atrial fibrillation. / Hung, Chen Ying; Lin, Ching Heng; Loh, El Wui; Ting, Chih Tai; Wu, Tsu Juey.

In: American Journal of Medicine, Vol. 126, No. 2, 01.02.2013.

Research output: Contribution to journalArticle

Hung, Chen Ying ; Lin, Ching Heng ; Loh, El Wui ; Ting, Chih Tai ; Wu, Tsu Juey. / CHADS2 score, statin therapy, and risks of atrial fibrillation. In: American Journal of Medicine. 2013 ; Vol. 126, No. 2.
@article{b27f56b78d3d43f6b54562e9dfd1d1b7,
title = "CHADS2 score, statin therapy, and risks of atrial fibrillation",
abstract = "Objective: Little is known about the effectiveness of statins on primary prevention of atrial fibrillation in elderly patients. This study aimed to evaluate the efficacy of statin treatment for atrial fibrillation prevention in elderly patients with hypertension, and to determine if comorbidity or CHADS2 (Congestive heart failure, Hypertension, Age ≥75 years, Diabetes mellitus, prior Stroke or transient ischemic attack) score can predict the effectiveness of statin treatment. Methods: Patients aged ≥65 years with hypertension were identified from a National Health Insurance research database (a systemic sampling from 2000 to 2009 with a total of 1,000,000 subjects). Medical records of 27,002 patients were used in this study, in which 2400 (8.9{\%}) were receiving statin therapy. Risk of new-onset atrial fibrillation in statin users and nonusers was analyzed. Results: During the 9-year follow-up period, 2241 patients experienced new-onset atrial fibrillation. Statin users were younger than nonusers (72.4 vs 73.4 years) but had a higher prevalence of ischemic heart disease, diabetes mellitus, stroke, and chronic renal disease. Overall, statin therapy reduced the risk of atrial fibrillation by 19{\%} (adjusted hazard ratio 0.81; 95{\%} confidence interval, 0.69-0.95; P =.009). Subgroup analysis showed that statin use was beneficial in patients with or without a particular comorbidity. The effectiveness of statins was significant in patients with CHADS2 score ≥2 (adjusted hazard ratio 0.69; 95{\%} confidence interval, 0.57-0.85; P <.001). However, statin therapy was not as beneficial in hypertensive patients without other cardiovascular comorbidities (CHADS 2 score =1). Conclusion: Statin therapy in elderly patients with hypertension reduces the risk of new-onset atrial fibrillation. Statins are more beneficial in patients with CHADS2 score ≥2 than in those with score of 1.",
keywords = "Atrial fibrillation, CHADS score, Hypertension, Statins",
author = "Hung, {Chen Ying} and Lin, {Ching Heng} and Loh, {El Wui} and Ting, {Chih Tai} and Wu, {Tsu Juey}",
year = "2013",
month = "2",
day = "1",
doi = "10.1016/j.amjmed.2012.06.027",
language = "English",
volume = "126",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - CHADS2 score, statin therapy, and risks of atrial fibrillation

AU - Hung, Chen Ying

AU - Lin, Ching Heng

AU - Loh, El Wui

AU - Ting, Chih Tai

AU - Wu, Tsu Juey

PY - 2013/2/1

Y1 - 2013/2/1

N2 - Objective: Little is known about the effectiveness of statins on primary prevention of atrial fibrillation in elderly patients. This study aimed to evaluate the efficacy of statin treatment for atrial fibrillation prevention in elderly patients with hypertension, and to determine if comorbidity or CHADS2 (Congestive heart failure, Hypertension, Age ≥75 years, Diabetes mellitus, prior Stroke or transient ischemic attack) score can predict the effectiveness of statin treatment. Methods: Patients aged ≥65 years with hypertension were identified from a National Health Insurance research database (a systemic sampling from 2000 to 2009 with a total of 1,000,000 subjects). Medical records of 27,002 patients were used in this study, in which 2400 (8.9%) were receiving statin therapy. Risk of new-onset atrial fibrillation in statin users and nonusers was analyzed. Results: During the 9-year follow-up period, 2241 patients experienced new-onset atrial fibrillation. Statin users were younger than nonusers (72.4 vs 73.4 years) but had a higher prevalence of ischemic heart disease, diabetes mellitus, stroke, and chronic renal disease. Overall, statin therapy reduced the risk of atrial fibrillation by 19% (adjusted hazard ratio 0.81; 95% confidence interval, 0.69-0.95; P =.009). Subgroup analysis showed that statin use was beneficial in patients with or without a particular comorbidity. The effectiveness of statins was significant in patients with CHADS2 score ≥2 (adjusted hazard ratio 0.69; 95% confidence interval, 0.57-0.85; P <.001). However, statin therapy was not as beneficial in hypertensive patients without other cardiovascular comorbidities (CHADS 2 score =1). Conclusion: Statin therapy in elderly patients with hypertension reduces the risk of new-onset atrial fibrillation. Statins are more beneficial in patients with CHADS2 score ≥2 than in those with score of 1.

AB - Objective: Little is known about the effectiveness of statins on primary prevention of atrial fibrillation in elderly patients. This study aimed to evaluate the efficacy of statin treatment for atrial fibrillation prevention in elderly patients with hypertension, and to determine if comorbidity or CHADS2 (Congestive heart failure, Hypertension, Age ≥75 years, Diabetes mellitus, prior Stroke or transient ischemic attack) score can predict the effectiveness of statin treatment. Methods: Patients aged ≥65 years with hypertension were identified from a National Health Insurance research database (a systemic sampling from 2000 to 2009 with a total of 1,000,000 subjects). Medical records of 27,002 patients were used in this study, in which 2400 (8.9%) were receiving statin therapy. Risk of new-onset atrial fibrillation in statin users and nonusers was analyzed. Results: During the 9-year follow-up period, 2241 patients experienced new-onset atrial fibrillation. Statin users were younger than nonusers (72.4 vs 73.4 years) but had a higher prevalence of ischemic heart disease, diabetes mellitus, stroke, and chronic renal disease. Overall, statin therapy reduced the risk of atrial fibrillation by 19% (adjusted hazard ratio 0.81; 95% confidence interval, 0.69-0.95; P =.009). Subgroup analysis showed that statin use was beneficial in patients with or without a particular comorbidity. The effectiveness of statins was significant in patients with CHADS2 score ≥2 (adjusted hazard ratio 0.69; 95% confidence interval, 0.57-0.85; P <.001). However, statin therapy was not as beneficial in hypertensive patients without other cardiovascular comorbidities (CHADS 2 score =1). Conclusion: Statin therapy in elderly patients with hypertension reduces the risk of new-onset atrial fibrillation. Statins are more beneficial in patients with CHADS2 score ≥2 than in those with score of 1.

KW - Atrial fibrillation

KW - CHADS score

KW - Hypertension

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=84872584350&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872584350&partnerID=8YFLogxK

U2 - 10.1016/j.amjmed.2012.06.027

DO - 10.1016/j.amjmed.2012.06.027

M3 - Article

C2 - 23331441

AN - SCOPUS:84872584350

VL - 126

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 2

ER -